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The effectsof the antiarrhythmic agent propafenone were
evaluated in 25 patients with recurrent symptomatic ven-
tricular tachycardia. Oral propafenone was given to a
maximal dose of 300 mg every 8 hours. Ten of the 25
patients developed side effects or had inadequate
suppression of spontaneous ventricular arrhythmias
during propafenone therapy. Electrophysiologic studies
were performed before and during drug therapy on the
15 patients who had a satisfactory clinical response. Pro-
pafenone increased the PR interval from 168 :t 46 to
188 ± 25 ms «(> < 0.007), the HV interval from 47 ±
10 to 65 ± 13ms (p < 0.005), the shortest atrial pacing
cycle length to maintain 1:1atrioventricular (AV) nodal
conduction from 385 ± 44 to 436 ± 42 ms (p < 0.005),
the ventricular effective refractory period from 231 ±
17 to 255 ± 19 ms (p < 0.001) and the ventricular
functional refractory period from 260 ± 15 to 278 ±
17 ms (p < 0.002).
Before propatenone therapy, alliS patients had ven-
tricular tachycardia induced by programmed ventricu-
lar stimulation. Durihg propafenone treatment, 12 pa-
In vitro studies on Purkinje fibers demonstrate that propa-
fenone, (2'-3-propylamino)-2-(hydroxy)-propoxy-3-phen-
ylpropiophenone, has electrophysiologic properties similar
to those of procainamide and encainide even though its
chemical structure is markedly different from the stucture
of these drugs (Fig. 1). In dogs, propafenone effectively
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tients still had ventricular tachycardia induced, and the
tachycardia cycle length significaAtly increased from
236 ± 44 to 374 ± 103 ms (p < 0.001). Ten patients
were considered to have satisfactory electrophysiologic
response to propafenone on the basis of either the ina-
bility to initiate ventricular tachycardia or a marked
increase in ventricular tachycardia cycle length associ-
ated with lack of symptoms during the indu~ed tachy-
cardia. These patients were discharged receiving pro-
pafenone. During a mean follow-up period of 11months,
8 of the 10 patients have remained free of ventricular
tachycardia, while 2 have had a recurrence.
Propafenone significantly depresses AV nodal and His-
Purkinje conduction, lengthens ventricular refractori-
nessand markedly increasesventricular tachycardia cycle
length. Furthermore, preliminary data suggest that in-
duction of ventricular tachycardia at electrophysiologic
study does not always augur recurrence of spontaneous
tachycardia.
(J Am Coil CardioI1985;5:1407-13)
suppresses ventricular tachycardia that occurs during acute
myocardial infarction (1). In human subjects, oral propa-
fenone is an effective agent ih the management of premature
ventricular complexes and chronic recurrent supraventric-
ular tachycardia (2-7) and does not appear to cause signif-
icant hemodynamic changes (8) or life-threatening toxic side
effects (9). The purpose of this study was to determine the
antiarrhythmic and electrophysiologic properties of oral pro-
pafenone in patients with ventricular tachycardia.
Methods
Study patients. All patients included in this study had
recurrent electrocardiographically documented episodes of
ventricular tachycardia or ventricular fibrillation not related
to drug therapy or acute myocardial infarction, and either
developed side effects or had recurrence of their arrhythmia
during therapy with all conventional antiarrhythmic agents.
0735-1097/85/$3.30
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Figure 1. Chemical structure of propafenone: (2'3-propylamino)-
2-(hydroxy)-propoxy-3-phenylpropiophenone.
Informed oral and written consent was obtained from the
patients before enrollment in the study. Electrophysiologic
testing was performed in the postabsorptive nonsedated state
after all cardiovascular medications were discontinued for
a period exceeding five times the elimination half-life of the
respective drug.
Twenty-five patients. 19 men and 6 women with a mean
age of 59 years, were entered into this study (Table I).
Cardiac diagnoses included arteriosclerotic heart disease,
17 patients; rheumatic heart disease, 2 patients; primary
electrical disease (that is, no structural heart disease as de-
fined by normal findings on coronary arteriography, ven-
triculography and echocardiography), 2 patients; idiopathic
dilated cardiomyopathy, 2 patients; valvular heart disease,
1 patient and mitral valve prolapse, 1 patient.
Electrophysiologic study. Two or more multipolar
electrode catheters were inserted percutaneously into the
Table 1. Patient Characteristics
right femoral vein and advanced to the heart under fluoro-
scopic guidance. The catheters were positioned in the high
right atrium, His bundle region and right ventricle. Intra-
cardiac electrograms and standard electrocardiographic leads
I, II, III and V I were displayed simultaneously on a mul-
tichannel oscilloscope and were recorded at a paper speed
of 50 to 150 mmls. The intracardiac and surface electro-
grams were recorded at frequencies of 30 to 500 and 0.1
to 20 Hz, respectively. Atrial and ventricular stimulation
was accomplished using a quadripolar catheter, with the
distal bipolar pair used for pacing and the proximal bipolar
pair for recording. Stimuli were twice latediastolic threshold
and 2.0 ms in duration for control and drug studies.
Our pacing protocol has been reported in detail else-
where (10,11). In brief, atrial and ventricular refractory
period determinations were performed using the extra-
stimulus technique. The shortest pacing cycle length yield-
ing 1: 1 atrioventricular (AV) nodal conduction was deter-
mined by pacing the high right atrium beginning at a cycle
length just shorter than the spontaneous cycle length and
decreasing the pacing cycle length by 10 to 20 ms until AV
nodal block occurred or the patient developed symptoms.
Protocol for induction of ventricular tachycardia. To
induce ventricular tachycardia, the following pacing tech-
niques were utilized: I) premature atrial stimulation at two
Case Age (yr) & Sex Heart Disease Arrhythmia
I 49M ASHD VF
2 52M ASHD VT-NS
3 50F ASHD VT-NS
4 58M ASHD VT·S
5 62M RHD VF
6 52M RHD VT-NS
7 70M ASHD VT-NS
8 49M MVP VT-NS
9 78M ASHD VT-S
10 61F ASHD VT-NS
II 67F ASHD VT-NS
12 53M ASHD VT-S
13 57M ASHD VT-S
14 40M ASHD VT-NS
15 73F ASHD VT-S
16 12M PED VF
17 74M PED VT·S
18 6lM ASHD Vf
19 52M ASHD VT-S
20 55M ASHD VT-S
21 59F ASHD VT-NS
22 27M CM VT-NS
23 62M ASHD VT-S
24 50M VHD VT-NS
25 71F CM VT-S
ASHD = arteriosclerotic heart disease; CM = cardiomyopathy; F = female; M = male; MVP = mitral
valveprolapse;PED = primaryelectricaldisease;RHD = rheumatic heartdisease;VF = ventricularfibrillation;
VHD = valvularheart disease; VT-NS = nonsustained ventricular tachycardia; VT-S = sustained ventricular
tachycardia.
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Table 2. Electrophysiologic Effects of Propafenone
Electrophysiologic Intervals No. of Cases Control Study (ms) Propafenone Study(ms) p Value
PR 15 168 ± 46 188 ± 25 < 0.007
QRS 15 106 ± 31 105 ± 22 NS
QTc 15 363 ± 30 388 ± 27 < 0.002
Spontaneous cycle length 15 773 ± 103 774 ± 41 NS
Atrial ERP 9 24 1 ± 21 262 ± 45 NS
Atrial FRP 9 276 ± 30 309 ± 67 NS
AH interval (NSR) 12 92 ± 19 101 ± 19 NS
Shortest CL with 1: I AVN condo 10 385 ± 44 436 ::!: 42 < 0.005
HV interval I I 47 ± 10 65 ::!: 13 < 0 .005
Ventricular ERP 13 231 ± 17 255 ± 19 < 0.00 1
Ventricular FRP 13 260 ± 15 278 ± 17 < 0.002
Ventricular tachycardia CL 12 236 ± 44 374 ± 103 <0.001
AVN = atrioventricular nodal; CL = cycle length; condo = conduction; ERP = effective refractory period; FRP = functional refractory period;
NS = not significant; NSR = normal sinus rhythm.
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Figure 3. Effects of propafenone on shortest paced cycle length
(CL) maintaining 1: I atrioventricular nodal (AVN) conduction
(COND.) during incremental right atrial pacing in 10 patients.
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Oral propofenone was administered at an initial dose of
150 mg every 8 to 12 hours. The dose was increased at 48
hour intervals to a maximal dose of 300 mg every 8 hours .
Cardiac rhythm was monitored continuously by telemetry
(Hewlett-Packard, model 78512A) before and during drug
administration.
Follow-up. Patients were discharged receiving propa-
fenone if ventricular tachycardia was not induced at elec-
trophysiologic study while they were receiving propafenone
or the induced ventricular tachycardia had a marked length-
ening of cycle length compared with the ventricular tachy-
cardia induced during the control study , and the patients
remained asymptomatic during ventricular tachycardia. During
follow-up, each patient was seen as an outpatient at I month
and , subsequently, at 3 month intervals by one of the in-
vestigators. Twenty-four hour electrocardiographic record-
ings were obtained at each outpatient visit.
Discriminant function. In a previous study of patients
with ventricular tachycardia initiated during amiodarone
therapy (i 2), multiple clinical and electrophysiologic vari-
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Figure 2. Effects of propafenone on HV interval during sinus
rhythm in II patients . The lines connect values for each patient
during control and propafenone therapy . Horizontal lines repre-
sent mean values.
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or more cycle lengths; 2) incremental atrial pacing to AV
block or development of patient symptoms; and 3) premature
ventricular stimulation using one or two extrastimuli intro-
duced during sinus rhythm and during ventricular pacing at
one or more cycle lengths (600, 500 and 400 ms). If ven-
tricular tachycardia was not induced at the first right ven-
tricular site tested , the protocol was repeated at a second
right ventricular site . All patient s had ventricular tachycar-
dia similar to their clinical ventricular tachycardia induced
from the right ventricle.
Drug protocol. Repeat electrophysiologic studies were
performed at least 48 hours after the maximal dose of pro-
pafenone was administered. For each patient , refractory pe-
riod determinations were performed at the same pacing cycle
length during the control and propafenone studies . Fur-
thermore, the entire programmed ventricular stimulation
protocol was repeated before it was concluded that ventric-
ular tachycardia was not inducible during drug therapy .
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Figure 4. Prolongation of ventricular effective refractory period
(ERP)during propafenone treatment in 13 patients.
abies were evaluated, and discriminant analysis was per-
formed to determine which combination of variables iden-
tified patients at risk of recurrent arrhythmia. A discriminant
function was developed that used change in induction of
repetitive ventricular responses , ventricular effective re-
fractory period or corrected QT (QTc) interval and mode
of ventricular tachycardia induction . The predictability of
this function (12) was evaluated in patients discharged with
ventricular tachycardia induced at electrophysiologic testing
during propafenone therapy.
Definitions. The effective refractory period ofthe atrium
and ventricle was defined as the longest SlS2 interval at
which S2 on two consecutive attempts failed to capture the
atrium or the ventricle, respectively .
Ventricular tachycardia was defined as three or more
consecutive ventricular complexes . Nonsustained ventric-
ular tachycardia was defined as ventricular tachycardia last-
ing less than 30 seconds ; sustained ventricular tachycardia
was defined as ventricular tachycardia lasting more than 30
seconds or requiring termination before that time due to
symptoms.
The QTc interval was determined using Bazett's for-
mula (13) .
Statistics. Data are expressed as mean ± I standard
deviation . The t test for paired data was used to test the
significance of change from the control value of electro-
physiologic variables within patients.
Results
Clinical adverse effects. During initial in-hospital ther-
apy, 10 patients discontinued taking propafenone (Patients
16 to 25) (Table 1). Five of these 10 patients continued to
have several daily episodes of nonsustained ventricular
tachycardia and were considered to have an unsatisfactory
clinical response. In the other five patients, propafenone
treatment was stopped before repeat electrophysiologic test-
ing because of one or more side effects that included nausea
in three patients, paresthesias in two patients and pleuritic
chest pain in one patient. Propafenone was discontinued in
one additional patient who developed pleuritic chest pain
after repeat electrophysiologic study. Both patients with
pleuritic chest pain had normal lung scans and no evidence
of venoocclusive disease , and serologic evaluation dem-
onstrated no autoimmune abnormality. Chest pain abated
without sequelae after discontinuation of propafenone ther-
Table 3. Effect of Propafenone on Ventricular Tachycardia Induction
VT Induced* Methodof Induction YT CL (ms)
Case Control Study Prop. SlUdy Control Study Prop. Study Control Study Prop. Study
I S S V,Yl RV2 350 490
2 4 S Y,YN3 Y,V2V3 250 280
3 II 3 Y'Y2V3 Y,V2Y3 230 340
4 6 6 V1V2V3 V,V2V3 210 390
5 18 S V,V2V3 V,V1 260 480
6 S NI V,VN3 180
7 6 S V,V2V3 V,VN3 260 330
8 3 NI V,V1V3 210
9 S S V,V1 V,V1 220 250
10 4 NI V,V2V3 160
II 18 38 V1V1V3 V,V2V3 260 370
12 S S Y1V1V3 RV2V3 260 570
13 s S V,V1V3 Y'Y2Y3 260 330
14 4 3 V,V2Y3 V1VN3 220 230
15 S S V'Y2V3 V,V1V3 210 430
*Maximal number of induced ventricular complexes if not sustained ventricular tachycardia. CL = cycle length; NI not induced; Prop.
propafenone; RV2 = one ventricularextrastimulus introduced during sinus rhythm;RV1V3 = two ventricularextrastimuli introducedduring sinus rhythm;
S = sustained; VT = ventriculartachycardia; VT-NS = nonsustained ventriculartachycardia; VT-S = sustainedventriculartachycardia; V,V2 = one
ventricularextrastimulus introducedduring ventricularpacing; V,V2V3 = two ventricularextrastimuli introduced during ventricularpacing.
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Figure 5. Administration of propafenone in 12 patients increases
ventricular tachycardia (VT) cycle length.
had the same rate as the clinical ventricular tachycardia.
Since the configuration of the clinical nonsustained tachy-
cardia was rarely known for all 12 electrocardiographic leads,
it is unclear whether the induced tachycardia had the iden-
tical configuration as the clinical tachycardia.
During repeat electrophysiologic propafenone study,
ventricular tachycardia could no longer be initiated in three
patients, despite testing with the complete protocol at two
right ventricular sites. However, ventricular tachycardia still
was induced in 12 patients. For these 12 patients, the mean
tachycardia cycle length significantly lengthened from
236 ± 44 ms at control study to 374 ± 103 ms (p < 0.001)
during propafenone treatment (Fig. 5).
Four patients were considered to have an unsatisfactory
response to propafenone therapy on the basis of results of
electrophysiologic testing. Three of these patients had 30
ms or less prolongation of ventricular tachycardia cycle
length during propafenone therapy compared with control
values. In the fourth patient, ventricular tachycardia cycle
length increased from 260 to 330 ms, but the patient became
hypotensive during ventricular tachycardia. Propafenone was
discontinued in these four patients and in one additional
patient, noted earlier, who developed side effects to the
drug before hospital discharge.
Follow-up. Ten patients were discharged receiving oral
propafenone therapy and have had a mean follow-up of 11
months (Table 3, Fig. 6). The three patients who had no
ventricular tachycardia induced at propafenone electro-
physiologic study have remained asymptomatic and had no
ventricular tachycardia on outpatient ambulatory 24 hour
electrocardiographic recordings. Two of seven patients (Cases
1 and 12) who had ventricular tachycardia initiated during
propafenone electrophysiologic study have had symptomatic
recurrent sustained ventricular tachycardia and their treat-
ment has been changed to other antiarrhythmic agents. The
remaining five patients (Cases 3, 4, 5, 7 and 11) remain
asymptomatic and have shown no evidence of ventricular
tachycardia recurrence by outpatient 24 hour continuous
electrocardiographic recordings. Subsequent to discharge,
PROPAFENONECONTROL
600
550
.. 500
E
450
J:
I- 400
C>
z 350w
.J
W
300
.J
o 250
>-
o
200
I-
> 150
n=12
100
apy, and both patients refused drug rechallenge. The cause
for their pleuritic chest pain is unknown.
Electrophysiologic changes (Table 2). Fifteen of the
25 patients showed marked lessening of their spontaneous
ventricular arrhythmias and underwent repeat electrophys-
iologic study: 13 patients had complete suppression of spon-
taneous ventricular tachycardia and in 2 patients only one
three-complex episode of ventricular tachycardia was noted
within 24 hours before repeat study. Significant increases
during propafenone treatment occurred in the PR and QTc
intervals, HV interval, ventricular effective and functional
refractory periods and shortest atrial pacing cycle length
maintaining 1: I AV nodal conduction (Fig. 2 to 4).
At control electrophysiologic study, ventricular tachy-
cardia was induced in allIS patients (Table 3). Tachycardia
similar in rate and configuration to the clinical ventricular
tachycardia was induced in patients with a history of sus-
tained ventricular tachycardia. In patients with a history of
nonsustained ventricular tachycardia, induced tachycardia
15
Figure 6. Eleven month follow-up of 15
patients treated with propafenone. VT =
ventricular tachycardia. Seetextfordetails.
12
VT Induced
7~S
3
No VT Induced
•3
Discharged
5 - Asymptomatic
2 - Recurrent VT
Drug Changed Asymptomatic
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one of these patients developed nausea that resolved when
the total daily propafenone dose was reduced from 900 to
750 mg daily.
Discussion
This study demonstrates that propafenone substantially
alters the electrophysiologic properties of multiple tissue
types in human subjects and can be used effectively to treat
patients with recurrent ventricular tachycardia. Propafenone
prolonged both the PR and QTc intervals, depressed con-
duction through the AV node and His-Purkinje system and
lengthened right ventricular refractoriness. The increase in
atrial refractoriness did not reach statistical significance.
The electrophysiologic changes that occurred with pro-
pafenone administered intravenously at dosages of 1 to 2
mg/kg (14) differed somewhat from the changes reported
in our study of oral administration of the drug; for example,
there was a significant increase in the PR interval during
oral but not intravenous drug treatment, whereas the QRS
duration was significantly prolonged with intravenous but
not oral drug therapy. Both forms of drug administration
prolonged ventricular effective refractory period.
Antiarrhythmic properties. Propafenone was an effec-
tive antiarrhythmic drug in our group of patients whose
ventricular arrhythmias were not previously controlled with
conventional agents . Fifteen of 20 patients who received
the maximal dose of propafenone (900 mg daily) demon-
strated a marked reduction in spontaneous episodes of ven-
tricular tachycardia. During electrophysiologic drug testing,
although only 3 of 15 patients had no inducible ventricular
tachycardia, the tachycardia cycle length was markedly pro-
longed in 8 of the other 12 patients (Fig. 5). For all 12 of
these patients, the tachycardia rate decreased from 254 to
160 beats/min, and this degree of slowing is greater than
that noted by us during testing with most other drugs (15).
Clinical efficacy. It is unknown whether induction of
ventricular tachycardia at electrophysiologic study while the
patient receives propafenone portends a recurrence of spon-
taneous ventricular tachycardia after hospital discharge. We
tested this hypothesis in seven patients who had initiation
of ventricular tachycardia that was relatively slow and well
tolerated during propafenone therapy . Five of these seven
patients have remained asymptomatic during follow-up (Fig.
6), as have the three patients in whom tachycardia could
not be induced at repeat electrophysiologic study. Twenty-
four hour electrocardiographic monitoring at 3 month in-
tervals also has not documented episodes of ventricular
tachycardia. Although tachycardia may have recurred in
these patients, they have remained asymptomatic. Two pa-
tients developed recurrences of symptomatic ventricular
tachycardia, and these patients subsequently have had re-
currences of tachycardia while receiving amiodarone.
It is noteworthy that applying the same discriminant func-
tion developed for amiodarone (12) to identify patients at
risk for recurrence of ventricular tachycardia during drug
therapy when ventricular tachycardia is initiated at electro-
physiologic study, we correctly classified all seven patients
discharged taking propafenone. These are preliminary data
and need confirmation from a study of a larger series of
patients.
Conclusion. Oral propafenone is an effective antiar-
rhythmic drug that is well tolerated and suitable for long-
term therapy in patients with recurrent ventricular tachy-
cardia . Results from electrophysiologic testing suggest that
induction of ventricular tachycardia does not necessarily
predict recurrence of spontaneous ventricular tachycardia,
a result similar to that reported for amiodarone therapy (16).
Further studies are needed to substantiate this observation.
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